

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Haohai Biological Technology Co., Ltd.\***

**上海昊海生物科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6826)**

**EXTRAORDINARY GENERAL MEETING HELD ON  
FEBRUARY 14, 2017  
AND  
APPOINTMENT OF EXECUTIVE DIRECTOR**

The Board is pleased to announce that all resolutions set out in the Notice of Extraordinary General Meeting were duly passed at the Extraordinary General Meeting held on February 14, 2017.

**THE POLL RESULTS OF EXTRAORDINARY GENERAL MEETING**

References are made to the Notice of Extraordinary General Meeting (“**EGM**”) dated December 29, 2016 of the Company (the “**Notice of EGM**”) and the circular dated December 29, 2016 (the “**Circular**”). For the detailed content of the resolutions considered at the EGM, shareholders may refer to the Circular. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same respective meanings as those defined in the Circular

The Board is pleased to announce that the EGM was held at 10 a.m., Tuesday, February 14, 2017 at 23/F, WenGuang Plaza, No.1386 Hongqiao Road, Changning District, Shanghai, the PRC, by way of an on-site meeting, and the resolutions set out in the Notice of EGM were passed by way of poll. Computershare Hong Kong Investor Services Limited, the Company’s H share registrar, was appointed as the scrutineer for vote counting at the EGM.

The holding of the EGM was in compliance with the relevant PRC laws and regulations, the Listing Rules and the Articles of Association. The meeting was convened by the Board and chaired by Dr. Hou Yongtai, the Chairman of the Board.

As at the date of the EGM, the total number of Shares issued by the Company was 160,045,300 Shares, comprising 120,000,000 Domestic Shares and 40,045,300 H Shares, which was the total number of Shares entitling the shareholders of the Company (the “**Shareholders**”) to attend and vote for or against or abstain from voting in respect of the resolutions proposed at the EGM. Shareholders holding an aggregate of 128,150,718 Shares with voting rights, representing approximately 80.07% of the total issued Shares, attended the EGM either in person or by proxy. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of any of the resolutions proposed at the EGM as set out in Rule 13.40 of the Listing Rules and no Shareholder was required under the Listing Rules to abstain from voting at the EGM. There was no restriction on any Shareholders to cast votes on any of the proposed resolutions at the EGM. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on the resolutions proposed at the EGM.

The poll results of the EGM were as follows:

Ordinary Resolutions		Number of Votes (approximately %)		
		For	Against	Abstain
1.	To consider and, if thought fit, approve the further change in use of proceeds from the Global Offering.	127,453,418 (99.46%)	697,300 (0.54%)	0 (0%)
2.	To consider and, if thought fit, appoint Mr. Tang Minjie as an executive Director of the Third Session of the Board and to authorize the Board to do all such acts and things to give effect to such matters.	126,927,218 (99.05%)	1,223,500 (0.95%)	0 (0%)

As more than half of the votes were cast in favour of the ordinary resolutions numbered 1 & 2 set out above at the EGM, all such resolutions were duly passed as ordinary resolutions of the Company.

## **APPOINTMENT OF EXECUTIVE DIRECTOR**

The Company is pleased to announce that upon approval by the EGM, Mr. Tang Minjie has been appointed as an executive Director of the Third Session of the Board of the Company for a term commencing from the date of the EGM until the expiry of the term of office of the Third Session of the Board.

The biographical details of Mr. Tang Minjie and other information disclosed in accordance with Rule 13.51(2) of the Listing Rules were set out in the Circular. As at the date of this announcement, there was no change in such information.

Mr. Tang Minjie will enter into a service agreement with the Company for serving as an executive Director. Mr. Tang will not receive any remuneration from the Company in respect of his appointment as an executive Director but is entitled to receive emolument for serving as financial controller of the Company.

By order of the Board  
**Shanghai Haohai Biological Technology Co., Ltd.**  
**Hou Yongtai**  
*Chairman*

Shanghai, PRC, February 14, 2017

*As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Mr. Huang Ming, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie and Mr. Gan Renbao; and the independent non-executive directors of the Company are Mr. Chen Huabin, Mr. Shen Hongbo, Mr. Li Yuanxu, Mr. Zhu Qin and Mr. Wong Kwan Kit.*

*\* For identification purpose only*